drugset / Trial / NCT06565611
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).
Timeline
- Start
- 2024-08-05
- Primary completion
- 2025-02-05
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bremelanotide | Peptide | — | Subcutaneous |
| Comparator | Tirzepatide | Peptide | — | Subcutaneous |